Abstract
Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V et al.: Treatment ofWaldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20: 2327-2333, 2002
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M: Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18: 214-226, 2000
Delgado J, Canales MA, Garcia B, Alvarez-Ferreira J, Garcia-Grande A, Hernandez-Navarro F: Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: case report and review of the literature. Am J Hematol 69: 127-131, 2002
Torrey JJ, Katakkar SB: Treatable meningeal involvement inWaldenstrom's macroglobulinemia. Ann Intern Med 101: 345-347, 1984
Abad S, Zagdanski AM, Brechignac S, Thioliere B, Brouet JC, Mariette X: Neurolymphomatosis in Waldenstrom's macroglobulinaemia. Br J Haematol 106: 100-103, 1999
Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ et al.: CD20-Directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24: 272-279, 2001
Woimant F, Schanen A, Bertail MA, Dupuy M, Lecoz P, Haguenau M et al.: Myelopathy manifesting as macroglobulinemia. Ann Med Interne (Paris) 136: 121-124, 1985
Raizer J, DeAngelis L, Zelenetz A, Abrey L: Activity of Rituximab in primary central nervous system lymphoma (PCNSL). Proc ASCO 19: 166a, 2000
Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 11: 374-375, 2000
Harjunpaa A, Wiklund T, Janes R, Collan J, Rosenberg J, Lee D et al.: Complement activation in blood and central nervous system after Rituximab treatment of B-Cell lymphoma. Proc ASCO19: 40a, 2000
Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52: 1701-1704, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liberato, B., Riethmuller, A., Comenzo, R.L. et al. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy. J Neurooncol 63, 207–211 (2003). https://doi.org/10.1023/A:1023912425610
Issue Date:
DOI: https://doi.org/10.1023/A:1023912425610